Mike Moyer
Host, LifeSci Advisors
Replay available
PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call
PDS Biotechnology Corporation (NASDAQ: PDSB) Q4 2025 earnings conference call, held 2026-03-30. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Frank Badu-Addo
Chief Executive Officer
Dr. Kirk Shepard
Chief Medical Officer
Lars Bosgaard
Chief Financial Officer
Mayank Montani
Analyst, BeWriter Securities
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Pds Biotechnology Corporation.
Replay transcript excerpt
WEBVTT 00:00:02.005 -- 00:00:07.534 Greetings and welcome to the PDS Biotech fourth quarter 2025 earnings call. 00:00:07.534 -- 00:00:10.538 At this time, all participants are in listen-only mode. 00:00:10.538 -- 00:00:13.503 A question and answer session will follow the formal presentation. 00:00:13.503 -- 00:00:18.371 If anyone should require operator assistance during the conference, please press star 00:00:18.371 -- 00:00:22.658 zero on your telephone keypad. As a reminder, this conference is being recorded. 00:00:22.658 -- 00:00:28.587 I would now like to turn the conference over to your host, Mike Moyer, with LifeSci Advisors. 00:00:28.587 -- 00:00:31.488 Thank you. You may begin. 00:00:32.026 -- 00:00:35.786 Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's fourth quarter 00:00:35.786 -- 00:00:39.502 2025 results and clinical programs update call. 00:00:39.502 -- 00:00:43.288 I'm joined on a call today by the following members of the company's management team. 00:00:43.288 -- 00:00:46.373 Dr. Frank Badu-Addo, Chief Executive Officer, Dr. 00:00:46.373 -- 00:00:51.021 Kirk Shepard, Chief Medical Officer, and Lars Bosgaard, Chief Financial Officer. 00:00:51.021 -- 00:00:55.127 Dr. Badu-Addo will begin with an overview of the company's recent highlights in its clinical 00:00:55.127 -- 00:00:59.915 development program. Dr. Shepard will review the data and rationale behind the amendment 00:00:59.915 -- 00:01:04.322 the company recently adopted to its Phase III Versatile 003 trial, 00:01:04.322 -- 00:01:09.121 and Mr. Bosgaard will review The financial results for the quarter ended December 31st, 00:01:09.121 -- 00:01:11.364 2025. Following 00:01:11.364 -- 00:01:15.110 management's prepared remarks, we will open the call to questions from cove...